Hangzhou Duoxi Biotechnology

Hangzhou DuoXi Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company has established a comprehensive ADC technology platform that includes proprietary linkers, potent payloads, and site-specific conjugation technologies designed to improve the therapeutic window and stability of its candidates. Its lead program, DX126-26, is a HER2-targeting ADC currently in Phase 2 clinical trials for various solid tumors. DuoXi Biotech's robust pipeline also features candidates targeting TROP2, MUC1, and other validated oncology markers, positioning it as a significant player in the competitive Chinese ADC landscape.